Thymox Technology

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Thymox Technology - overview

Location

Sherbrooke, QC, Canada

Primary Industry

Chemicals

About

Thymox Technology specializes in creating biodegradable antimicrobial products that effectively combat harmful pathogens, leveraging the natural properties of thymol derived from thyme oil to deliver environmentally friendly disinfection solutions. Thymox Technology develops innovative antimicrobial solutions aimed at various sectors. Founded by Serge Auray, the company is headquartered in Sherbrooke, Canada. In May 2017, Thymox secured USD 4.


6 mn in a Series B funding round led by Cycle Capital Management and Desjardins Capital, raising a total of USD 4. 6 mn to date. Thymox, a brand under Laboratoire M2, specializes in biodegradable, high-performance antimicrobial products with thymol as the active ingredient. Its offerings include disinfectants for surfaces, farms, greenhouses, biopesticides, and animal hoof care products, effectively targeting pathogens including bacteria and viruses.


Thymox distributes its products across North America and Europe, addressing the needs of agricultural, animal health, and commercial cleaning sectors with a focus on eco-friendly solutions. Thymox primarily operates through B2B transactions, catering to distributors and commercial entities. Its revenue model is driven by the sale of products like the Thymox Disinfectant Spray, provided under various arrangements. While specific pricing details are undisclosed, the products are positioned competitively within the market, reflecting strong demand in the disinfectant sector.


Thymox plans to leverage its recent funding from the USD 4. 6 mn Series B round to enhance its product offerings and expand into new markets. The company is focusing on developing new antimicrobial products targeted for launch in the coming years and aims to penetrate additional regions beyond North America and Europe. This strategic initiative is expected to enhance Thymox's market position and drive further growth.


Current Investors

Cycle Capital Management, Desjardins Capital

Primary Industry

Chemicals

Sub Industries

Consumer Products, Agricultural Chemicals

Website

www.thymox.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.